- Home
- CNEY vs IMRN Comparison
CNEY vs IMRN Comparison
Compare CNEY & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- IMRN
- Stock Information
- Founded
- CNEY 2018
- IMRN 1994
- Country
- CNEY China
- IMRN Australia
- Employees
- CNEY N/A
- IMRN N/A
- Industry
- CNEY Major Chemicals
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- IMRN Health Care
- Exchange
- CNEY Nasdaq
- IMRN Nasdaq
- Market Cap
- CNEY 8.0M
- IMRN 9.2M
- IPO Year
- CNEY 2021
- IMRN N/A
- Fundamental
- Price
- CNEY $2.34
- IMRN $1.93
- Analyst Decision
- CNEY
- IMRN Strong Buy
- Analyst Count
- CNEY 0
- IMRN 1
- Target Price
- CNEY N/A
- IMRN $5.00
- AVG Volume (30 Days)
- CNEY 372.1K
- IMRN 47.9K
- Earning Date
- CNEY 01-01-0001
- IMRN 08-29-2025
- Dividend Yield
- CNEY N/A
- IMRN N/A
- EPS Growth
- CNEY N/A
- IMRN N/A
- EPS
- CNEY N/A
- IMRN N/A
- Revenue
- CNEY $50,957,974.00
- IMRN $4,777,422.00
- Revenue This Year
- CNEY N/A
- IMRN N/A
- Revenue Next Year
- CNEY N/A
- IMRN N/A
- P/E Ratio
- CNEY N/A
- IMRN N/A
- Revenue Growth
- CNEY N/A
- IMRN 48.63
- 52 Week Low
- CNEY $1.56
- IMRN $1.50
- 52 Week High
- CNEY $31.75
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- CNEY 51.98
- IMRN 59.97
- Support Level
- CNEY $1.56
- IMRN $1.80
- Resistance Level
- CNEY $2.57
- IMRN $1.93
- Average True Range (ATR)
- CNEY 0.30
- IMRN 0.07
- MACD
- CNEY 0.01
- IMRN 0.01
- Stochastic Oscillator
- CNEY 71.76
- IMRN 99.45
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.